中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
5,25R-胆甾烯-3beta,26-二醇 | (25R)-cholest-5-ene-3β,26-diol | 20380-11-4 | C27H46O2 | 402.661 |
—— | (25R)-cholest-5-en-3β,16β,26-triol | 31327-56-7 | C27H46O3 | 418.66 |
—— | (25R)-26-hydroxycholest-4-en-3-one 26-acetate | 71486-01-6 | C29H46O3 | 442.682 |
—— | (25R)-3b-(tert-Butyldimethylsilyloxy)cholest-5-en-26-ol | 192187-70-5 | C33H60O2Si | 516.924 |
—— | (25R)-3β,26-bis (tert-butyldimethylsilyloxy)-cholest-5-ene | 192187-69-2 | C39H74O2Si2 | 631.186 |
薯蓣皂素 | diosgenin | 512-04-9 | C27H42O3 | 414.629 |
中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
5,25R-胆甾烯-3beta,26-二醇 | (25R)-cholest-5-ene-3β,26-diol | 20380-11-4 | C27H46O2 | 402.661 |
—— | (25R)-7α,26-dihydroxycholest-4-en-3-one | 192187-67-0 | C27H44O3 | 416.645 |
—— | (25R)-26-hydroxycholest-4-en-3-one 26-acetate | 71486-01-6 | C29H46O3 | 442.682 |
—— | Acetic acid (2R,6R)-6-((8S,9S,10R,13R,14S,17R)-10,13-dimethyl-3-oxo-2,3,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-methyl-heptyl ester | 192187-74-9 | C29H44O3 | 440.667 |
—— | Acetic acid (2R,6R)-6-((8S,9S,10R,13R,14S,17R)-10,13-dimethyl-3-oxo-8,9,10,11,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-methyl-heptyl ester | 192187-75-0 | C29H42O3 | 438.651 |
Previously, we identified a series of steroids (1–6) that showed potent anti-virus activities against respiratory syncytial virus (RSV), with IC50 values ranging from 3.23 to 0.19 µM. In this work, we first semi-synthesized and characterized the single isomer of 5, 25(R)-26-acetoxy-3β,5α-dihydroxycholest-6-one, named as (25R)-5, in seven steps from a commercially available compound diosgenin (7), with a total yield of 2.8%. Unfortunately, compound (25R)-5 and the intermediates only showed slight inhibitions against RSV replication at the concentration of 10 µM, but they possessed potent cytotoxicity activities against human bladder cancer 5637 (HTB-9) and hepatic cancer HepG2, with IC50 values ranging from 3.0 to 15.5 µM without any impression of normal liver cell proliferation at 20 µM. Among them, the target compound (25R)-5 possessed cytotoxicity activities against 5637 (HTB-9) and HepG2 with IC50 values of 4.8 µM and 15.5 µM, respectively. Further studies indicated that compound (25R)-5 inhibited cancer cell proliferation through inducing early and late-stage apoptosis. Collectively, we have semi-synthesized, characterized and biologically evaluated the 25R-isomer of compound 5; the biological results suggested that compound (25R)-5 could be a good lead for further anti-cancer studies, especially for anti-human liver cancer.
此前,我们发现了一系列类固醇(1-6),它们对呼吸道合胞病毒(RSV)具有很强的抗病毒活性,IC50值从3.23到0.19 µM不等。在这项工作中,我们首先从市售化合物 diosgenin(7)出发,通过七个步骤半合成并表征了 5、25(R)-26-乙酰氧基-3β,5α-二羟基胆甾烷-6-酮的单一异构体,命名为 (25R)-5,总产率为 2.8%。遗憾的是,化合物 (25R)-5 及其中间体在 10 µM 浓度下对 RSV 的复制只有轻微的抑制作用,但它们对人膀胱癌 5637(HTB-9)和肝癌 HepG2 具有很强的细胞毒性活性,IC50 值从 3.0 µM 到 15.5 µM 不等,在 20 µM 浓度下对正常肝细胞的增殖没有任何影响。其中,目标化合物(25R)-5 对 5637(HTB-9)和 HepG2 具有细胞毒性活性,IC50 值分别为 4.8 µM 和 15.5 µM。进一步研究表明,化合物 (25R)-5 可通过诱导早期和晚期细胞凋亡抑制癌细胞增殖。总之,我们对化合物 5 的 25R 异构体进行了半合成、表征和生物学评价;生物学结果表明,化合物 (25R)-5 可能是进一步抗癌研究,尤其是抗人类肝癌研究的良好先导。